Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANDY-CANE: Linagliptin vs Glipizide in T2D and CKD
NCT02608177Completed
- Sponsor
- University of Washington
- Start
- Nov 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by University of Washington. Primary endpoint: Glucose Time in Range. Started Nov 2015; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02608177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608177.